Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 16/20 | 0.53 |
| ▸ | CYP2A13 | Q16696 | 3/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27871918 | 0.83 | CYP2A13 (0.49) | OPRL1CYP2A13DRD2DRD4DRD3 | |
| SCHEMBL1805087 | 0.83 | CYP2A13 (0.48) | OPRL1CYP2A13 | |
| SCHEMBL1803399 | 0.81 | ALDH1A1 (0.45) | OPRL1CYP2A13 | |
| SCHEMBL27888227 | 0.76 | OPRL1 (0.42) | OPRL1 | |
| SCHEMBL1808960 | 0.76 | OPRL1 (0.42) | OPRL1 | |
| SCHEMBL1813166 | 0.76 | OPRL1 (0.49) | OPRL1 | |
| SCHEMBL27871912 | 0.74 | OPRL1 (0.40) | OPRL1DRD2DRD4DRD3 | |
| SCHEMBL11972622 | 0.73 | OPRL1 (0.87) | OPRL1 | |
| SCHEMBL15251825 | 0.73 | OPRL1 (0.54) | OPRL1 | |
| SCHEMBL11972686 | 0.71 | OPRL1 (0.40) | OPRL1DRD2DRD4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2501704-B1 | Spiropiperidine compounds as oral-1 receptor antagagonisten | LILLY CO ELI (US) | 2013-09-18 | — | — | EP | disclosed |
| EP-2501704-A1 | SPIROPIPERIDINE COMPOUNDS AS ORL-1 RECEPTOR ANTAGONISTS | Eli Lilly and Company (US) | 2012-09-26 | — | — | EP | disclosed |
| CN-102666550-A | Spiropiperidine compounds as ORL-1 receptor antagonists | LILLY CO ELI | 2012-09-12 | — | — | CN | disclosed |
| US-20120214784-A1 | SPIROPIPERIDINE COMPOUNDS AS ORL-1 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2012-08-23 | — | — | US | disclosed |
| WO-2011060217-A1 | SPIROPIPERIDINE COMPOUNDS AS ORL-1 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2011-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214784-A1 | SPIROPIPERIDINE COMPOUNDS AS ORL-1 RECEPTOR ANTAGONISTS | OPRL1, ORMDL3, OGFRL1 | OPRL1 1/4885CYP2A13 2960/4885DRD2 350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.